Loading...
Docoh

Avadel Pharmaceuticals (AVDL)

Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Company profile

Ticker
AVDL
Exchange
Website
CEO
Gregory Divis
Employees
Location
Fiscal year end
Former names
FLAMEL TECHNOLOGIES SA
SEC CIK
Subsidiaries
1) Avadel US Holdings, Inc. • B. Avadel Legacy Pharmaceuticals, LLC • C. Avadel Management Corporation • D. Avadel CNS Pharmaceuticals, LLC • 2) Flamel Ireland Ltd. • 3) Avadel Investment Company, Ltd. • 4) Avadel France Holding SAS • A. Avadel Research SAS • 5) Avadel Finance Ireland • A. Avadel Finance Cayman Ltd. ...

AVDL stock data

Analyst ratings and price targets

Last 3 months

Calendar

9 May 22
9 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 60.87M 60.87M 60.87M 60.87M 60.87M 60.87M
Cash burn (monthly) (no burn) (no burn) 10.25M 8.46M 11.35M 7.33M
Cash used (since last report) n/a n/a 44.12M 36.4M 48.85M 31.55M
Cash remaining n/a n/a 16.75M 24.47M 12.02M 29.33M
Runway (months of cash) n/a n/a 1.6 2.9 1.1 4.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Aug 22 Peter J. Thornton Stock Option ADSs Grant Acquire A No No 4.79 42,000 201.18K 42,000
3 Aug 22 Linda Palczuk Stock Option ADSs Grant Acquire A No No 4.79 42,000 201.18K 42,000
3 Aug 22 McCamish Mark Anthony Stock Option ADSs Grant Acquire A No No 4.79 42,000 201.18K 42,000
3 Aug 22 Geoffrey Michael Glass Stock Option ADSs Grant Acquire A No No 4.79 42,000 201.18K 42,000
3 Aug 22 Ende Eric J Stock Option ADSs Grant Acquire A No No 4.79 42,000 201.18K 42,000
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • On June 30, 2020, we announced the sale of the Hospital Products, including our three FDA-approved commercial products, Akovaz, Bloxiverz and Vazculep, as well as Nouress, to the Exela Buyer. As a result of the sale, the Company recorded a gain on the sale of the Hospital Products of $45,760 and no longer recorded revenue, cost of products, intangible amortization and changes to the fair value of the contingent consideration related to these products subsequent to the Closing Date.
  • Research and development (“R&D”) expenses decreased by $3,338 or 16.3% during the year ended December 31, 2021 as compared to the same period in 2020. This decrease was driven by lower clinical studies expense due to the completion of the FT218 clinical study during the year ended December 31, 2020, offset by higher pre-NDA approval activities and higher compensation expense.
  • Selling, general and administrative (“SG&A”) expenses increased by $36,090 or 111.4% during the year ended December 31, 2021 as compared to the prior year. This increase was driven primarily by the Company’s continued commercial preparations and launch readiness activities for potential approval of FT218. These activities included an increase in marketing and market research costs of approximately $12,700 and an increase in other launch planning and preparation activities totaling $5,000. Compensation costs increased by approximately $11,000 due to an increase in headcount, primarily in commercial and medical affairs. Legal, technology and insurance costs increased by approximately $7,200.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accuracy, API, background, breached, classification, clinician, competitor, confidential, confirmed, correction, cumulative, DCE, deficiency, denominated, diminished, dollar, entry, estoppel, euro, evidence, exposed, frequency, functional, Hikma, implemented, inclusion, inflation, influenced, introduction, inventorship, Italy, judicial, managerial, misappropriated, notably, opportunity, owed, prevailing, rapidly, redeem, remediated, remediation, Rome, safer, stratified, stressor, strong, survey, therapy, translate, translated, translation, unclean, version, viewed, World
Removed: academic, adrenergic, advance, agent, agonist, Akovaz, alpha, amortizable, anesthesia, annually, arriving, assumed, attributable, bankruptcy, beta, bifurcation, billion, blocking, Bloxiverz, Board, branded, Breaking, Broadfin, Buyer, buying, CEO, charge, charged, civil, claimed, closing, collected, comparing, computed, customary, customer, cysteine, dated, Decision, deferred, Design, designated, detail, developing, discharge, disclose, dismissal, Earlsfort, earned, effort, electronically, entitled, entity, ephedrine, established, Exela, Exhibit, exit, expedient, expired, FASB, fiscal, Flamel, FLML, forecasted, forma, found, France, free, French, furnished, generate, generated, goodwill, governing, Hedging, holding, Horizon, hydrochloride, hypotension, improving, initiated, initiative, injectable, injection, installment, intangible, International, intravenously, invoicing, list, longer, maintained, make, Maker, Membership, met, methylsulfate, MIPA, modified, monthly, neostigmine, neuromuscular, Newly, niche, Noctiva, nutrition, offered, opening, operation, parenteral, partially, perform, permitted, phenylephrine, phone, planned, polymer, practicable, practical, practice, premium, preparation, pro, production, profit, proprietary, proxy, receivable, refer, represent, requirement, reserve, resource, responsible, restructuring, resulted, retained, retrospective, return, reverse, Rollforward, room, Sant, Sarl, SAS, satisfied, satisfy, scope, segment, separated, settled, simplification, Simplifying, source, statement, sterile, Stick, subsequently, Subtopic, sulfate, surgery, Terrace, therapeutic, thereof, timeline, Topic, transferred, typically, ultimate, ultimately, uncertainty, unconditional, underlying, utilize, variable, Vazculep, wholesale, workforce

Reddit threads